Having trouble accessing articles? Reset your cache.

Targeting toxicity

Novonco ribonucleotide reductase, HMT inhibitors could be safer than predecessors

Novonco Therapeutics Inc. is developing a pipeline of targeted cancer therapies that were designed at City of Hope and University of California Irvine to be less toxic than either first-generation inhibitors, or parent molecules.

Its lead compound is COH29, a small molecule ribonucleotide reductase inhibitor that is slated to enter Phase I testing this year in solid tumors.

Ribonucleotide reductase catalyzes the formation of deoxyribonucleotide triphosphates (dNTPs) that support DNA synthesis and tumor proliferation. The enzyme is the target of marketed drugs including hydroxyurea and gemcitabine.

Read the full 870 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers